Compare · AZN vs ETON
AZN vs ETON
Side-by-side comparison of AstraZeneca PLC (AZN) and Eton Pharmaceuticals Inc. (ETON): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and ETON operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $261.92B, about 225.9x ETON ($1.16B).
- Over the past year, AZN is down 10.3% and ETON is up 193.8% - ETON leads by 204.1 points.
- AZN has been more active in the news (12 items in the past 4 weeks vs 7 for ETON).
- AZN has more recent analyst coverage (25 ratings vs 7 for ETON).
- Company
- AstraZeneca PLC
- Eton Pharmaceuticals Inc.
- Price
- $168.85-0.24%
- $42.37+13.91%
- Market cap
- $261.92B
- $1.16B
- 1M return
- -5.56%
- +31.10%
- 1Y return
- -10.32%
- +193.83%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2018
- News (4w)
- 12
- 7
- Recent ratings
- 25
- 7
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Eton Pharmaceuticals Inc.
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. It also develops ET-105, a lamotrigine for oral suspension; DS-300, a cysteine injection; DS-100, a dehydrated alcohol injection; ET-104, a zonisamide oral suspension; ET-101, a topiramate oral suspension; and ET-203, an ephedrine ready-to-use injection. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca downgraded by HSBC Securities
- SEC Form 6-K filed by AstraZeneca PLC
- Officer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,265 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 11-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest ETON
- Amendment: Large owner Opaleye Management Inc. sold $1,063,033 worth of shares (28,315 units at $37.54) (SEC Form 4)
- Canaccord Genuity initiated coverage on Eton Pharmaceuticals with a new price target
- Large owner Opaleye Management Inc. sold $1,063,033 worth of shares (28,315 units at $37.54) (SEC Form 4)
- President & CEO Brynjelsen Sean exercised 227,500 shares at a strike of $1.20, increasing direct ownership by 27% to 1,061,194 units (SEC Form 4)
- Chief Business Officer Krempa David converted options into 10,000 shares, increasing direct ownership by 37% to 37,025 units (SEC Form 4)
- Large owner Opaleye Management Inc. sold $4,768,637 worth of shares (126,685 units at $37.64) (SEC Form 4)
- SEC Form 4 filed by Chief Business Officer Krempa David
- Director Adams Jennifer Mckie exercised 50,000 shares at a strike of $3.78 and sold $1,623,795 worth of shares (50,000 units at $32.48) (SEC Form 4)
- Eton Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 3 filed by new insider Matthews Judith M.